Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you use biomarkers to improve risk prediction in patients with ADPKD during early disease stages?
Bais T, et al., PMID 40067938
Related Questions
How do you clinically distinguish between pericardial effusion from volume overload versus uremic pericarditis in advanced CKD?
Do you recommend SGLT2 inhibitors for patients with Fabry disease and proteinuria despite ACEi/ARB use?
How do you approach the management of ADPKD in pregnancy, considering the need to stop tolvaptan therapy?
Do you prioritize adding a GLP-1 receptor agonist over an SGLT-2 inhibitor in patients with CKD related to type 2 diabetes, uncontrolled proteinuria despite being on an ACEi, and obesity?
Do you plan to initiate combination therapy with an SGLT-2 inhibitor and finerenone, instead of an SGLT-2 inhibitor alone, when treating patients with proteinuric chronic kidney disease and type 2 diabetes in light of the CONFIDENCE trial findings?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
Would you recommend the use of an ACE inhibitor to patients with Type 1 diabetes mellitus who are normotensive but have persistent moderate proteinuria?
Do you recommend temporarily holding SGLT2 inhibitors in patients with CKD who are undergoing CT imaging with intravenous contrast?
Do you advise your patients with CKD to consume a set amount of fluids daily in an attempt to prevent disease progression?
How do you advise a patient with CKD who wants to take an herbal medication that is not known to be nephrotoxic, given that herbal medications are not regulated?
